A bill to educate health care providers and the public on biosimilar biological products, and for other purposes.
Sponsor and status
Sponsor. Junior Senator for New Hampshire. Democrat.
Last Updated: Apr 16, 2021
Length: 2 pages
What legislators are saying
This bill incorporates provisions from:
H.R. 1873: Advancing Education on Biosimilars Act of 2021
Introduced on Mar 12, 2021. 100% incorporated. (compare text)
S. 164 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number S. 164. This is the one from the 117th Congress.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
GovTrack.us. (2021). S. 164 — 117th Congress: Advancing Education on Biosimilars Act of 2021. Retrieved from https://www.govtrack.us/congress/bills/117/s164
“S. 164 — 117th Congress: Advancing Education on Biosimilars Act of 2021.” www.GovTrack.us. 2021. June 19, 2021 <https://www.govtrack.us/congress/bills/117/s164>
Advancing Education on Biosimilars Act of 2021, Pub. L. No. 117-8, S. 164, 117th Cong..
|title=S. 164 (117th)
|accessdate=June 19, 2021
|author=117th Congress (2021)
|date=February 2, 2021
|quote=Advancing Education on Biosimilars Act of 2021
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.